Skip to content
OpenCapital
Get started

Supernus Pharmaceuticals SUPN Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclassification

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.62B+62.8%

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept supn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Supernus Pharmaceuticals's fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, reclassification?
Supernus Pharmaceuticals (SUPN) reported fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, reclassification of $33.44M in Q1 2026.